John W. Grunden, Pharm.D.
As Regional Director of Medical Affairs, Ophthalmology (US/EU/CAN) for Merck, Dr. Grunden is responsible for U.S. and global glaucoma medical activities, including the conduct of clinical trials, investigator-initiated research grants, strategic planning, and interactions with global regulatory agencies.
Prior to his appointment at Merck in 2011, he worked in global medical affairs at Pfizer and at Pharmacia where he supported the Ophthalmology Franchise from the time of Xalatan’s launch in 1996. He has also held numerous academic appointments.
Dr. Grunden received his Doctor of Pharmacy degree from the University of Utah after obtaining a Bachelor of Pharmacy degree from Washington State University. Following a residency in Clinical Pharmacy Practice, he completed a specialized residency at the University Hospital and Clinics in Salt Lake City, Utah.
Dr. Grunden was elected to the Glaucoma Research Foundation Board of Directors in January 2009. He currently serves as Chair of the Science Committee.
